Efficacy*

WinRho® SDF demonstrates excellent efficacy in Rho(D)-positive nonsplenectomized patients.^1,2

* Study was performed using WinRho®/WinRho® SD
† Dose = 20-75 µg/kg (100-375 IU/kg); Response = platelet increase to ≥20,000/mm³
‡ Dose = 25-55 µg/kg (125-275 IU/kg); Response = platelet increase to ≥ 50,000/mm³ and doubling of baseline platelet count

WinRho® SDF Liquid is Bioequivalent to WinRho® SDF Lyophilized

In two comparative pharmacokinetic studies (n=101), the formulations were bioequivalent following IV administration based on area under the curve to 84 days and had comparable pharmacokinetics following IM administration. Both formulations also had similiar elimination half-lives. WinRho®  SDF must be administered via the intravenous route for the treatment of ITP.

WinRho® Response Time

A multicenter, randomized, controlled trial (n=146) comparing WinRho® to IVIG and prednisone in children with acute ITP was conducted. After WinRho® SDF therapy, the mean time to achieve platelet count of ≥ 20,000/mm³ was 1.9 days and ≥ 50,000/mm³ was 2.8 days.

When comparing the different therapies for time to platelet count ≥ 20,000/mm³ or ≥ 50,000/mm³, no statistically significant differences were observed among treatment groups, with a range of 1.3 to 1.9 days and 2.0 to 3.2 days for IVIG and prednisone, respectively.^1,2

* Study was performed using WinRho®
† Dose = 25 µg/kg (125 IU/kg) for 2 days

WinRho® SDF Liquid is Bioequivalent to WinRho® SDF Lyophilized

In two comparative pharmacokinetic studies (n=101), the formulations were bioequivalent following IV administration based on area under the curve to 84 days and had comparable pharmacokinetics following IM administration. Both formulations also had similar elimination half-lives. WinRho® SDF must be administered via the intravenous route for the treatment of ITP.

*Study was performed using WinRho®/WinRho® SD

Please see Important Safety Information and Prescribing Information.